English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET

MPS-Authors
/persons/resource/persons147352

Zander,  Thomas
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147315

Thomas,  Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147249

Neumaier,  Bernd
Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147154

Dietlein,  Markus
Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Scheffler, M., Kobe, C., Zander, T., Nogova, L., Kahraman, D., Thomas, R. K., et al. (2012). Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. Lung Cancer, 77(3), 617-620. doi:10.1016/j.lungcan.2012.05.110.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0026-D6EF-E
Abstract
© 2012 Elsevier Ireland Ltd. All rights reserved.